Compare · AVTR vs TBIO
AVTR vs TBIO
Side-by-side comparison of Avantor Inc. (AVTR) and Telesis Bio Inc. (TBIO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVTR and TBIO operate in Biotechnology: Laboratory Analytical Instruments (Health Care), so they compete in similar markets.
- AVTR carries a market cap of $10.41B.
- AVTR has hit the wire 8 times in the past 4 weeks while TBIO has been quiet.
- AVTR has more recent analyst coverage (25 ratings vs 4 for TBIO).
- Company
- Avantor Inc.
- Telesis Bio Inc.
- Price
- -
- -
- Market cap
- $10.41B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- 2021
- News (4w)
- 8
- 0
- Recent ratings
- 25
- 4
Avantor Inc.
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, and clinical trial kits. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Telesis Bio Inc.
Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis. It is also developing MRT5500 for the treatment of SARS-CoV-2. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. has a collaboration and license agreement with Sanofi Pasteur Inc. The company was founded in 2011 and is headquartered in Lexington, Massachusetts.
Latest AVTR
- EVP, Chief Operating Officer Blenn Mary covered exercise/tax liability with 2,900 shares, decreasing direct ownership by 1% to 250,484 units (SEC Form 4) to satisfy withholding obligation
- EVP, Chief Legal & Compliance Sokenu Claudius was granted 62,305 shares, increasing direct ownership by 25% to 313,533 units (SEC Form 4)
- EVP, Chief HR Officer Hankamer Brittany was granted 46,728 shares, increasing direct ownership by 19% to 295,592 units (SEC Form 4)
- Avantor Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- SEC Form 10-Q filed by Avantor Inc.
- SEC Form 8-K filed by Avantor Inc.
- Avantor® Reports Third Quarter 2026 Results
- Avantor appoints new Chief Information Officer
- Healthcare Stocks Rushing Higher, with Oncology Push, Breakout Test, and Lilly’s Next Growth Chapter
- Avantor® to Report Third Quarter 2026 Earnings on Wednesday, October 28, 2026
Latest TBIO
- Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis
- Telesis Bio Secures up to $21 Million to Accelerate Adoption of Groundbreaking Gibson SOLA Technology for Rapid DNA and mRNA Synthesis
- SEC Form 15-12G filed by Telesis Bio Inc.
- SEC Form EFFECT filed by Telesis Bio Inc.
- SEC Form EFFECT filed by Telesis Bio Inc.
- SEC Form POS AM filed by Telesis Bio Inc.
- SEC Form POS AM filed by Telesis Bio Inc.
- SEC Form S-8 POS filed by Telesis Bio Inc.
- SEC Form S-8 POS filed by Telesis Bio Inc.
- SEC Form S-8 POS filed by Telesis Bio Inc.